A Comprehensive Review of Solriamfetol to Treat Excessive Daytime Sleepiness
Copyright © 1964–2024 by MedWorks Media Inc, Los Angeles, CA All rights reserved. Printed in the United States..
Purpose of Review: This is a comprehensive review of the literature regarding the use of Solriamfetol for excessive daytime sleepiness. It covers the background and current therapeutic approaches to treating excessive daytime sleepiness, the management of common comorbidities, and the existing evidence investigating the use of Solriamfetol for this purpose.
Recent Findings: Excessive daytime sleepiness leads to worse quality of life, a medical sequela and significant economic cost. There are multiple phenotypes of excessive daytime sleepiness depending on the comorbidity making treatment challenging. Due to the complexity of etiology there is not a cure for this ailment. Solriamfetol is a norepinephrine/dopamine dual reuptake antagonist that can be used to manage daytime sleepiness. Solriamfetol was first approved by the FDA in 2018 for use in excessive daytime sleepiness associated with obstructive sleep apnea and narcolepsy. Ongoing literature has proved this drug to be a safe and effective alternative pharmacotherapy.
Summary: Recent epidemiological data estimate up to one-third of the general adult population suffers from excessive daytime sleepiness. There is no cure to daytime somnolence and current pharmacotherapeutic regimens have worrisome side effect profiles. Solriamfetol is a new class of drug that offers a safe and effective alternative option for clinical providers treating excessive daytime sleepiness.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:54 |
|---|---|
| Enthalten in: |
Psychopharmacology bulletin - 54(2024), 1 vom: 04. März, Seite 65-86 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fuller, Mitchell C [VerfasserIn] |
|---|
| Themen: |
47E5O17Y3R |
|---|
| Anmerkungen: |
Date Completed 08.03.2024 Date Revised 08.03.2024 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM369392426 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369392426 | ||
| 003 | DE-627 | ||
| 005 | 20240308232900.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240307s2024 xx |||||o 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n1320.xml |
| 035 | |a (DE-627)NLM369392426 | ||
| 035 | |a (NLM)38449471 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fuller, Mitchell C |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A Comprehensive Review of Solriamfetol to Treat Excessive Daytime Sleepiness |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.03.2024 | ||
| 500 | |a Date Revised 08.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 1964–2024 by MedWorks Media Inc, Los Angeles, CA All rights reserved. Printed in the United States. | ||
| 520 | |a Purpose of Review: This is a comprehensive review of the literature regarding the use of Solriamfetol for excessive daytime sleepiness. It covers the background and current therapeutic approaches to treating excessive daytime sleepiness, the management of common comorbidities, and the existing evidence investigating the use of Solriamfetol for this purpose | ||
| 520 | |a Recent Findings: Excessive daytime sleepiness leads to worse quality of life, a medical sequela and significant economic cost. There are multiple phenotypes of excessive daytime sleepiness depending on the comorbidity making treatment challenging. Due to the complexity of etiology there is not a cure for this ailment. Solriamfetol is a norepinephrine/dopamine dual reuptake antagonist that can be used to manage daytime sleepiness. Solriamfetol was first approved by the FDA in 2018 for use in excessive daytime sleepiness associated with obstructive sleep apnea and narcolepsy. Ongoing literature has proved this drug to be a safe and effective alternative pharmacotherapy | ||
| 520 | |a Summary: Recent epidemiological data estimate up to one-third of the general adult population suffers from excessive daytime sleepiness. There is no cure to daytime somnolence and current pharmacotherapeutic regimens have worrisome side effect profiles. Solriamfetol is a new class of drug that offers a safe and effective alternative option for clinical providers treating excessive daytime sleepiness | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a OSA | |
| 650 | 4 | |a dopamine | |
| 650 | 4 | |a narcolepsy | |
| 650 | 4 | |a norepinephrine | |
| 650 | 4 | |a obstructive sleep apnea | |
| 650 | 4 | |a solriamfetol | |
| 650 | 7 | |a solriamfetol |2 NLM | |
| 650 | 7 | |a 939U7C91AI |2 NLM | |
| 650 | 7 | |a Carbamates |2 NLM | |
| 650 | 7 | |a Phenylalanine |2 NLM | |
| 650 | 7 | |a 47E5O17Y3R |2 NLM | |
| 650 | 7 | |a Dopamine Antagonists |2 NLM | |
| 700 | 1 | |a Carlson, Samuel |e verfasserin |4 aut | |
| 700 | 1 | |a Pysick, Haley |e verfasserin |4 aut | |
| 700 | 1 | |a Berry, Vince |e verfasserin |4 aut | |
| 700 | 1 | |a Tondryk, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Swartz, Hayden |e verfasserin |4 aut | |
| 700 | 1 | |a Cornett, Elyse M |e verfasserin |4 aut | |
| 700 | 1 | |a Kaye, Adam M |e verfasserin |4 aut | |
| 700 | 1 | |a Viswanath, Omar |e verfasserin |4 aut | |
| 700 | 1 | |a Urits, Ivan |e verfasserin |4 aut | |
| 700 | 1 | |a Kaye, Alan D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Psychopharmacology bulletin |d 1966 |g 54(2024), 1 vom: 04. März, Seite 65-86 |w (DE-627)NLM000009520 |x 2472-2448 |7 nnns |
| 773 | 1 | 8 | |g volume:54 |g year:2024 |g number:1 |g day:04 |g month:03 |g pages:65-86 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 54 |j 2024 |e 1 |b 04 |c 03 |h 65-86 | ||